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Abstract
Background: Meta-analysis is a valuable tool for combining evidence from multiple studies. Network meta-analysis
is becoming more widely used as a means to compare multiple treatments in the same analysis. However, a network
meta-analysis may exhibit inconsistency, whereby the treatment effect estimates do not agree across all trial designs,
even after taking between-study heterogeneity into account. We propose two new estimation methods for network
meta-analysis models with random inconsistency effects.
Methods: The model we consider is an extension of the conventional random-effects model for meta-analysis to the
network meta-analysis setting and allows for potential inconsistency using random inconsistency effects. Our first new
estimation method uses a Bayesian framework with empirically-based prior distributions for both the heterogeneity
and the inconsistency variances. We fit the model using importance sampling and thereby avoid some of the
difficulties that might be associated with using Markov Chain Monte Carlo (MCMC). However, we confirm the
accuracy of our importance sampling method by comparing the results to those obtained using MCMC as the gold
standard. The second new estimation method we describe uses a likelihood-based approach, implemented in the
metafor package, which can be used to obtain (restricted) maximum-likelihood estimates of the model parameters
and profile likelihood confidence intervals of the variance components.
Results: We illustrate the application of the methods using two contrasting examples. The first uses all-cause
mortality as an outcome, and shows little evidence of between-study heterogeneity or inconsistency. The second
uses “ear discharge" as an outcome, and exhibits substantial between-study heterogeneity and inconsistency. Both
new estimation methods give results similar to those obtained using MCMC.
Conclusions: The extent of heterogeneity and inconsistency should be assessed and reported in any network
meta-analysis. Our two new methods can be used to fit models for network meta-analysis with random inconsistency
effects. They are easily implemented using the accompanying R code in the Additional file 1. Using these estimation
methods, the extent of inconsistency can be assessed and reported.
Keywords: Network meta-analysis, Importance sampling, Random inconsistency effects, Informative priors
Background
Meta-analysis is an established tool for pooling evidence
from multiple studies. In conventional meta-analyses,
each study contributes a single estimated effect to the
analysis. In this conventional univariate setting, the esti-
mated effects of the studies are given weights based on
the studies’ precisions, where more precise studies receive
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more weight. The estimated effects are then pooled by
taking a weighted average using these weights, to give a
single estimated effect that is intended to describe the
population of studies.
The simplest model that is typically used in meta-
analysis is the common-effects (or “fixed effect") model.
In this model, it is assumed that there is one true treat-
ment effect which is measured to within-study statistical
error by every study. However, in many applications, this
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assumption is implausible as between-study heterogene-
ity is often observed and/or thought to be present. In
such cases, a random-effects model [1] is often employed.
In a random-effects model, the true underlying treat-
ment effects from each study are assumed to come from
a common distribution whose expectation describes the
average effect in the population. We seek to estimate the
parameters of this common distribution in order to make
statistical inferences.
Network meta-analysis [2, 3] is an extension of con-
ventional meta-analysis that allows the comparison of
multiple treatments in a single analysis. Network meta-
analysis is particularly useful as multiple treatments can
be compared even when there is little or no direct evi-
dence available for some pairs of treatments. A network
meta-analysis may be either arm-based or contrast-based
and the debate concerning which approach is to be pre-
ferred is sometimes fierce [4, 5]. Briefly, arm-based anal-
yses model the average outcome data in each treatment
arm of each study; for example, the mean of a continuous
measurement or the log odds of success on a treatment
arm. See Piepho et al. [6] for a closely-related discus-
sion on this issue. Contrast-based analyses instead model
estimated treatment effects using study-specific reference
treatments, for example, the mean difference between
continuous measurements or the log odds ratio of suc-
cess in one treatment arm compared to another. In this
paper we use a contrast-based approach, which is the
more conventional approach in meta-analysis and other
settings [4].
As in a standard meta-analysis, it is important to
account for between-study heterogeneity in a network
meta-analysis and so a random-effects approach is typi-
cally adopted (in the absence of heterogeneity, the model
collapses to a common-effects model, as we will see in our
first example below). An additional issue in the context of
a network meta-analysis is the potential for a lack of con-
sistency in the estimated effects: For example, in a single
three-arm trial of treatments A, B, and C, it is necessarily
true that the relative effect of treatment C compared to A
is equal to the estimated relative effect of C compared to
B plus the relative effect of B compared to A (i.e., “C – A =
(C – B) + (B – A)"), on an appropriate scale. This prop-
erty is known as “consistency”. In this case, all treatments
have been compared directly. A network meta-analysis,
which includes multiple studies providing a combination
of direct and indirect evidence about the relative effects of
various subsets of the treatments of interest, does not nec-
essarily possess this property across the entire network.
The absence of consistency in such a network is termed
“inconsistency”, and is the result of discrepancies between
direct and indirect treatment effect estimates.
A recently proposed model that allows for inconsis-
tency in networkmeta-analysis is Jackson’s model [7]. This
model includes an inconsistency variance component,
whose magnitude describes the extent of the inconsis-
tency across the network. In this model, inconsistency
is treated as an additional source of variation alongside
between-study heterogeneity, and is conceptualised and
estimated in a similar manner. To date, two estimation
methods have been proposed to fit this model: The first of
these methods [8] uses a Bayesian framework andMarkov
Chain Monte Carlo (MCMC) methods as implemented
in Win/OpenBUGS [9]. The second of these methods [7]
is an extension of the method for conventional random-
effects meta-analysis proposed by DerSimonian and Laird
[1] and is based on the decomposition of the Q statistic by
Krahn et al. [10].
The primary contribution of the present paper is
to introduce two new estimation methods for fitting
Jackson’s model. The first of these new methods imple-
ments the type of Bayesian meta-analysis suggested by
Jackson et al. [8] but here we propose using importance
sampling, rather than MCMC, to sample from the poste-
rior distribution and further, we make use of informative
prior distributions for the unknown variance components.
We consider this new method an improvement over the
previous Win/OpenBUGS implementation for two rea-
sons. First, by using importance sampling techniques, we
avoid difficulties associated with ‘burning-in’ the chains
and autocorrelation; we still encounter Monte Carlo error
however. For those who prefer to use MCMC, importance
sampling provides reassurance that the MCMC estimates
are reliable. Second, we take a fully Bayesian approach,
incorporating external information on unknown variance
components, where we are able to justify and defend our
choice of priors. Unknown variance components are diffi-
cult to estimate and using truly vague prior distributions
makes these, at best, extremely difficult to identify [11]. By
using appropriate informative priors, we are able to over-
come some of these theoretical and practical difficulties
that are associated with Bayesian analyses that attempt to
use vague priors, though these benefits come at the cost
of additional assumptions via the prior distributions.
The second new estimation method we describe uses a
likelihood-based approach to fit the model. We propose
this as an improvement to the previous classical estima-
tion method that is based on the method of moments [7].
Although the method of moments retains its advantages
of computational simplicity and semi-parametric nature,
likelihood-based methods are based on sufficient statis-
tics and so make use of all the available information in the
sample. In addition, inferences for variance components
are easily obtained in a likelihood framework.
The rest of the paper is set out as follows. We start
by describing our model for network meta-analysis and
explain how this may be modified to incorporate alterna-
tive models with random inconsistency effects. We then
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describe our two new estimationmethods.We apply these
estimationmethods to two contrasting examples.We then
conclude with a discussion.
Methods
In this section we describe the model and the two new
corresponding estimation methods. We will also explain
how to modify the methods to fit alternative models for
networkmeta-analysis with random inconsistency effects.
We use A, B, C, etc. to denote the treatment groups and d
to denote the study ‘design’, where the term ‘design’ refers
to the sets of treatment comparisons included in the study;
for example, all studies that compare the treatments A, B,
and C (and no others) belong to the same design, and if
this is the first design then d = 1 is taken to mean the
‘ABC design’. Our primary inferential interest is making
inferences about the average treatment differences (i.e., A
vs. B, A vs. C, B vs. C, and so on) among all the treatments
included in the network.
Themodel
Jackson’s model has been fully described previously [7],
though we present it briefly here for completeness.
This model is a special case of the model proposed by
Jackson et al. [8], which in turn is a special case of the
design-by-treatment interaction model [12, 13]. Briefly,
the design-by-treatment interaction model was inspired
by loop-inconsistency models [14] which add inconsis-
tency parameters to closed loops where inconsistencies
may arise; loop inconsistency models therefore directly
appeal to intuitive notions of inconsistency in network
meta-analysis. However, the form of the loop inconsis-
tency model, and therefore the inconsistencies that are
described, depends on the treatment ordering [12, 15].
In order to overcome this issue, the design-by-treatment
interaction model was developed [12, 13], which allows
every design to estimate a different set of treatment
effects. The inclusion of a design-by-treatment interaction
term has also been explored by Piepho [16].
Jackson et al. [8] suggested making particular paramet-
ric assumptions for the between-study heterogeneity and
inconsistency variance components and Jackson et al. [7]
further simplified matters by using normal within-study
approximations where the within-study covariance matri-
ces are treated as fixed and known. It is the modelling
framework of Jackson et al. [7] that we take as our basis
here and this model is given by
Ydi = δd + Bdi + ωd + di, (1)
where Ydi represents the cd × 1 vector of estimated treat-
ment effects from study i of design d, where cd is the
number of treatment arms in design dminus one. To con-
veniently define the estimated treatment effects in Ydi, we
choose a design-specific baseline treatment group (e.g., A
in the ABC design, B in the BC design). The entries of
Ydi are then obtained as the estimated treatment effects of
the cd treatment groups, in alphabetical order, compared
to the baseline treatment group (e.g., A vs. B and A vs.
C in the ABC design). Without loss of generality, we take
the design-specific baseline treatment group as the treat-
ment that appears first in the alphabet in each design, and
we assume that this choice has been made throughout,
though any reference treatment may be chosen for each
design. Model (1) has four components, and we describe
these next. See also previous accounts of this modelling
framework [7, 8] for further details.
We choose a reference treatment A and we denote the
average (i.e., across all designs and studies) treatment
effects in the network meta-analysis as δAB, δAC , and so
on, where we refer to these parameters as ‘basic parame-
ters’. Then δd represents the average treatment effects of
design d in terms of the basic parameters; for example, for
the design that includes treatments C, D and E only,
δd = (δAD − δAC , δAE − δAC)T . Wemake inferences about
treatment effects that are not relative to the reference
treatment A by making inferences about appropriate con-
trasts of the basic parameters, so that our framework
allows us to make inferences about any pair of treatments
included in the network.
The variance components
The between-study heterogeneity is modelled by the ran-
dom effects vector Bdi, where we assume that Bdi ∼
N(0, τ 2βPcd ), where Pcd is a square matrix of dimension
cd with ones on the diagonal elements and halves every-
where else. Similarly, the inconsistency is modelled by ωd,
where ωd ∼ N(0, τ 2ωPcd ). The ωd are called the inconsis-
tency effects and we make a distributional assumption for
these parameters.
The distributional assumptions made for the between-
study heterogeneity (i.e., Bdi) and the inconsistency ran-
dom effects (i.e., ωd) are motivated primarily because they
lead to a particularly simple model form and because it is
difficult to identify more complex models in the majority
of applications [7, 8]. It is the ωd that allow the differ-
ent designs to estimate different sets of treatment effects,
so that the ωd provide the design-by-treatment interac-
tion. The two unknown variance components, τ 2β and τ 2ω,
describe the extent of the additional (to the within-study)
variation in the data that is due to between-study varia-
tion and inconsistency, respectively. If τ 2ω = 0, then, to
within-study and conventional between-study variation,
all studies of all designs estimate the same set of treat-
ment effects (because then all ωd = 0). Hence τ 2ω = 0
is taken to indicate consistency. If instead τ 2ω > 0, then
the designs estimate different treatment effects and the
network is inconsistent, and then the treatment effects in
the ABC loop would not ‘add up’ in the way implied by
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the consistency assumption. We refer to τ 2β and τ 2ω as the
between-study variance and the inconsistency variance,
respectively.
The within-study variation is modelled by di, where we
assume that di ∼ N(0, Sdi), where Sdi is the within-study
covariance matrix. The within-study covariance matrix is
estimated in practice but is treated as fixed and known
in the analysis. If all studies are two-arm studies, and so
estimate a single treatment effect, model (1) is equivalent
to Lumley’s model [17].
The full model
Model (1) describes the estimated effects for each study.
In order to describe the entire dataset, we vertically stack
the Ydi to create Y, where model (1) implies that
Y ∼ N
(
Xδ, τ 2βM1 + τ 2ωM2 + S
)
, (2)
where δ is a vector that contains the basic parameters.
This vector is premultiplied by design matrixX, where the
design matrix ensures that model (2) provides the mean
structure implied by model (1). The block diagonal matrix
S contains the Sdi along the main block diagonal, so that
the within-study distributions in models (1) and (2) are
equivalent. Similarly, the terms τ 2βM1 and τ 2ωM2 ensure
the equivalence between the between-study and incon-
sistency variance structures, respectively, in models (1)
and (2). This is achieved by defining square matrices M1
and M2: M1 contains ones on the main diagonal, so that
M1ii = 1 for all i. Furthermore, for i = j,M1ij = 1/2 if the
corresponding entries (i.e., rows) of Y are from the same
study, and M1ij = 0 otherwise. We similarly define M2 as
containing ones on the main diagonal, so that M2ii = 1
for all i. Furthermore, for i = j, M2ij = 1 if the corre-
sponding entries of Y are from the same design and refer
to the same treatment effect, M2ij = 1/2 if they are from
the same design but refer to different treatment effects,
and M2ij = 0 otherwise. In the previous presentation
of the model [7] we used P1 and P2 to denote M1 and
M2, but we now useM to denote these matrices, in order
to avoid a clash of notation with Pcd . Matrices M1 and
M2 for example two are given in the Additional file 2 for
illustration.
Our methodology can be used to fit other models for
network meta-analysis with random inconsistency effects
by modifying matrix M2. We could also make alternative
assumptions about the form of the between-study hetero-
geneity by modifyingM1. Furthermore, we could incorpo-
rate further unknown variance parameters, by introducing
more products of M matrices and these unknown vari-
ances. In particular, this could allow models that use more
than one parameter to describe the between-study hetero-
geneity. However, introducing more than two unknown
variance components will make the model harder to iden-
tify and interpret.
The standard method for making inferences about the
average treatment effects in a classical framework
The standard method for making inferences about the
average treatment effects (across all studies of all designs)
in a classical framework initially estimates the unknown
variance components and then treats them as known
in the analysis [7, 18]. The analysis then proceeds as a
weighted regressionmodel, where all weights are regarded
as known. We denote classical estimates of the two
unknown variances as τ̂ 2β and τ̂ 2ω. We then define the esti-
mated total variance of Y to be V = τ̂ 2βM1 + τ̂ 2ωM2 + S.
The vector of basic parameters is then estimated as
δˆ = (XTV−1X)−1XTV−1Y, (3)
which is approximately normally distributed, centred at δ,
with covariance matrix
Var(δˆ) = (XTV−1X)−1. (4)
Hence statistical inference for the basic parameters,
such as hypothesis testing and calculating confidence
intervals, is easily performed. Inferences for average treat-
ment effects that compare pairs of treatments that do not
include treatment A can be obtained by applying this nor-
mal approximation to appropriate contrasts of the basic
parameters.
This conventional method does not take into account
the uncertainty in the unknown variance components,
which can have unfortunate implications for the accu-
racy of the statistical inference in small samples [7, 18].
Provided that this concern is not too serious however,
the main statistical difficulty lies in estimating τ 2β and τ 2ω.
The method of moments was previously proposed for this
purpose [7] but we show how to use likelihood-based
methods, and in particular restrictedmaximum likelihood
(REML), for this purpose below.
Bayesian methods
Bayesian analysis differs from frequentist analysis by
treating unknown parameters as random quantities and
assigning prior distributions to those quantities. These
prior distributions are combined with the data to make
inferences on the unknown parameters. It is necessary to
choose prior distributions for all parameters in a Bayesian
analysis. We will use informative independent lognormal
prior distributions for τ 2β and τ 2ω, which we denote as
τ 2β ∼ LN
(
μβ , σ 2β
)
and τ 2ω ∼ LN
(
μω, σ 2ω
)
. The choice of
hyperparameters
(
i.e.,μβ , σ 2β ,μω, σ 2ω
)
is discussed below.
Informative priors were chosen for the unknown variance
components because these are hard to identify in typical
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meta-analysis datasets with small numbers of studies. We
follow Turner et al. [19] in using lognormal priors because
they provide concrete proposals for priors of this type. We
use independent uniform priors for the basic parameters
δ, specified over a wide range to include the parame-
ter space where the likelihood is non-negligible. These
uniform priors are intended to be vague, which reflects
our lack of prior knowledge regarding the parameter esti-
mates, and choosing uniform rather than diffuse normal
priors simplifies the resulting posterior distributions.
Informative priors for heterogeneity
We directly follow Turner et al. [19] in using informa-
tive lognormal priors for the between-study variance, τ 2β .
Briefly, Turner et al. used the Cochrane Database of Sys-
tematic Reviews to model binary outcome data in 14,886
meta-analyses, and subsequently obtained predictive dis-
tributions for the between-study heterogeneity variance.
Their proposal is to use these predictive distributions as
priors in random-effects meta-analyses [20]. Their predic-
tive distributions cover eighty distinct settings, compris-
ing a combination of sixteen outcome types (e.g., all-cause
mortality, adverse events) and five types of intervention
comparisons (e.g., pharmacological vs. placebo/control).
We have no reason to believe that the extent of hetero-
geneity in pairwise meta-analyses would be different if
these trials were part of a network. Thus, in the absence of
informative priors for network meta-analysis we consider
it sensible to use the distributions of Turner et al. [19].
Based on the settings of our example datasets (see
below), the appropriate context-specific lognormal prior
distributions were chosen for the heterogeneity vari-
ance [19]. For the first example dataset, the lognormal
prior τ 2β ∼ LN(−3.50, 1.262) (2.5 %, 50 %, 97.5 %
quantiles (0.00, 0.03, 0.36)) was chosen, reflecting the
outcome of all-cause mortality and the comparison of
non-pharmacological treatments. For the second exam-
ple dataset, the lognormal prior τ 2β ∼ LN(−2.29, 1.582)
(2.5 %, 50 %, 97.5 % quantiles (0.00, 0.10, 2.24)) was
chosen, again reflecting the type of outcome, “symptoms
reflecting continuation of condition", and pharmacologi-
cal interventions.
Informative priors for inconsistency
Turner et al. [19] did not fit their model to network meta-
analysis datasets and so did not include inconsistency
as a source of additional variation. As a consequence,
their priors are not immediately applicable to the other
unknown variance component in our model, τ 2ω. In order
to make use of their informative priors, we suggest a sim-
ple and intuitive way to translate the priors of Turner
et al. [19] for τ 2β into priors for τ 2ω. In what follows, we
make frequent use of the standard results that a lognor-
mal distribution, LN(μ, σ 2), has a mean of exp(μ + σ 2/2)
and a variance of
(
exp
(
σ 2
)− 1) exp (2μ + σ 2). We use
a lognormal prior for τ 2ω, because it seems reasonable
to assume that inconsistency follows a similarly-shaped
distribution to heterogeneity.
Our method for translating priors for τ 2β into priors for
τ 2ω requires the analyst to choose a factor by which to scale
the mean of the prior for τ 2β , in order to obtain the mean
of the prior for τ 2ω. From the standard results above for the
lognormal distribution, we can easily obtain the mean and
variance of the prior distribution of τ 2β . We set the vari-
ance of the prior distribution for τ 2ω equal to that of τ 2β , to
reflect a similar degree of uncertainty in the two unknown
variances; we denote this variance as V. We then obtain
the mean M of the prior distribution of τ 2ω as the product
of the scale factor and the mean of the prior distribu-
tion of τ 2β . Then solving simultaneous equations using the
standard results for the lognormal distribution, we obtain
the required hyperparameters that provide mean M and
variance V for the prior distribution of τ 2ω as
μω = log(M) − 12
[
log
( V
M2 + 1
)]
, σ 2ω = log
( V
M2 + 1
)
.
(5)
As an example, the lognormal prior for heterogeneity
in the first example is LN(−3.50, 1.262). This prior dis-
tribution has a mean of exp(−3.50 + 1.262/2) = 0.067
and variance of (exp(1.262)−1) exp(2 × −3.50 + 1.262) =
0.017 (both rounded). Suppose we then decide to assume
that the inconsistency variance τ 2ω is likely to be non-
negligible, but also that it is likely to be considerably less
than the between-study τ 2β , and we reflect this by applying
a scaling factor of 0.5 to the mean of the prior distribu-
tion of τ 2β to obtain an informative prior for τ 2ω. Then
we use M = 0.067/2 = 0.0335 and variance V =
0.017, and (5) gives μω = −4.79 and σ 2ω = 1.672 (both
rounded), so that the prior distribution of τ 2ω is taken to be
LN(−4.79, 1.672).
We recognise that this way of deriving informative
priors for τ 2ω is somewhat speculative and, in particu-
lar, assumes that the amount of prior information that
we have about between-study heterogeneity is similar to
the amount of prior information that we have about the
inconsistency variance. Since we conceptualise inconsis-
tency as a particular form of additional variation between
studies, similarly to the way we conceptualise between-
study variation, it is not unreasonable to take the amount
of prior knowledge about the likely extent of inconsistency
as being similar to the likely extent of the between-study
heterogeneity.
Other methods may be employed to characterise the
prior for inconsistency. For example, one may wish to
specify a lognormal distribution based on the choice of
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quantiles, rather than choosing a mean and variance. Fur-
ther, a truncated distribution may be used, to limit the
distribution to what is deemed a plausible interval. How-
ever, we choose to specify the distribution in terms of
its mean and variance, as this makes clear the differences
between the chosen priors for heterogeneity and inconsis-
tency, and allows the parameters μω and σ 2ω to be easily
found using (5).
In order to present a range of possibilities for our exam-
ples below, we perform analyses assuming that the prior
mean of the inconsistency variance is equal to that of the
between-study heterogeneity variance, assuming that the
prior mean of the inconsistency variance is half that of the
between-study heterogeneity variance, and finally assum-
ing that the prior mean of the inconsistency variance is
one tenth that of the between-study heterogeneity vari-
ance. These analyses cover a wide range of possibilities:
the first of these analyses is intended to reflect the notion
that the inconsistency is as severe as the between-study
heterogeneity, whilst the final analysis assumes that the
consistency assumption is a reasonable description of the
data while still acknowledging the possibility that some
inconsistency may be present.
As with the decision to use lognormal prior distribu-
tions characterised by mean and variance, other choices
may be made with regards to the form of the informative
prior for the inconsistency variance. In the main paper
we present results using an informative prior with a mean
of half of that of the informative prior for heterogeneity.
In the Additional file 3, it can be seen for example two
that the greater the mean of the prior for inconsistency,
the more the point estimate for inconsistency resembles
the frequentist estimate in Table 2. However, the intervals
of uncertainty around the inconsistency estimates make
definitive statements difficult when comparing these vari-
ance components. It is possible to use a prior for incon-
sistency with a greater mean than that of the prior for
heterogeneity, however, in the face of high inconsistency
we would discourage the use of network meta-analysis.
Importance sampling
Importance sampling [21] is a technique that can be used
for estimation when the posterior distribution is difficult
or impossible to obtain analytically, which is the case here.
Importance sampling has been used previously to under-
take meta-analyses [19, 22]. MCMC is also often used
for this purpose and is more powerful than importance
sampling. However, importance sampling is adequate for
relatively simple models such as ours, and avoids prob-
lems associated with burn-in and autocorrelation of the
simulated realisations of the posterior distribution. In
importance sampling, simulated samples of all parameters
are drawn independently from a proxy distribution that is
straightforward to sample from, and that ideally resembles
the true distribution of interest. However, importance
sampling algorithms can fail to converge if the tails of the
proxy distribution are too thin. Hence we include a scal-
ing factor s in the importance sampling algorithm below
to ensure that the proxy distributions have heavy tails.
The samples drawn from the proxy distribution are then
weighted using the ratio of the density of the true distribu-
tion of interest to the proxy density, where these densities
are evaluated using the simulated values. Any numerical
summary of the simulated values from the proxy distribu-
tion, when weighted in this way, give the corresponding
summary from the true distribution. In the context of
Bayesian statistics, this true distribution that we wish to
sample from is the posterior distribution.
In order to describe the importance sampling algorithm
that we use, we define some further quantities. We define
τ˜ 2β and τ˜ 2ω to be the means of the corresponding prior
distributions, so that τ˜ 2β = exp(μβ + σ 2β/2) and τ˜ 2ω =
exp(μω + σ 2ω/2). We then define V˜ = τ˜ 2βM1 + τ˜ 2ωM2 + S
which, if we take the estimates of the unknown variance
components as their prior means, is the estimated covari-
ance matrix of Y from model (2). We then define ˜δ =
(XT V˜−1X)−1XT V˜−1Y and ˜δvar = (XT V˜−1X)−1, where ˜δ
and ˜δvar are the corresponding classically estimated vector
of basic parameters and its covariance matrix, respec-
tively. We condition on the observed data in a Bayesian
analysis, which means that the above quantities denoted
using the ‘tilde’ notation are treated as constants.
We propose simulating from the following multivariate
proxy distribution in our importance sampling algorithm,
where we simulate each of these three random variables
independently:
δ∗ ∼N
(
˜δ, s ˜δvar
)
, τ 2∗β ∼ LN
(
μβ , σ 2β
)
, τ 2∗ω ∼ LN
(
μω , σ 2ω
)
,
(6)
where s denotes the scaling factor used in the importance
sampling algorithm. The asterisks in Eq. (6) indicate a
simulated random draw from the proxy distribution. The
intuition that underlies the proxy distribution in (6) is that
samples inmeta-analysis are often small and so contain lit-
tle information about the unknown variance components.
Hence the priors of τ 2β and τ 2ω are likely to resemble their
posteriors, but the priors can be expected to have heav-
ier tails, as desired in importance sampling algorithms,
because the posteriors include both the information in
the prior and the data. Hence the priors of the unknown
variance components are highly suitable as proxy distribu-
tions and their use simplifies the formula for the weights
below.
The proxy distribution of δ∗ is motivated by the stan-
dard method for making inferences in the classical frame-
work described above: We take the posterior distribution
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of δ to be approximately normally distributed with mean
equal to the classical estimate and covariance equal to s
times the corresponding classical covariance matrix of the
estimated effects, where we use the prior means (instead
of the point estimates) of the unknown variance compo-
nents in this classical analysis. The reason for choosing
this proxy distribution for δ is that we know the clas-
sical and Bayesian inferences for the basic parameters
will in general be in reasonable agreement, but also that
standard classical analyses, by ignoring the uncertainty
in the unknown variance components, will provide artifi-
cially small standard errors. See the examples of Jackson
et al. [7] for demonstrations of this. By using the prior
means of the unknown variance components in the classi-
cal estimation that underlies the motivation for the proxy
distribution for δ, we continue to assume that there is
relatively little information about the unknown variance
components in the sample. In large samples, where there
is more information about these parameters, we might
therefore prefer to use point estimates of τ 2β and τ 2ω in the
classical estimation that underlies the proxy distribution
for δ.
Finally, we require s ≥ 1 to ensure that the proxy dis-
tribution has heavier tails than the posterior distribution,
and to overcome the tendency of the standard classical
analysis to understate the uncertainty in the basic param-
eters compared to the Bayesian analysis.We follow Turner
et al. [19] and use s = 4 for this purpose, which is a suitably
large value that compensates for artificially small classical
standard errors that are only half their Bayesian counter-
parts (posterior standard deviations). To summarise, (6)
is an intuitively appealing proxy distribution that can be
expected to have heavy tails but otherwise resemble the
posterior distribution quite well.
As stated above, the simulated samples from the proxy
distribution are weighted by the ratio of the densities
of the true distribution to the proxy distribution, evalu-
ated at the simulated values. Here the true distribution is
the correct posterior distribution implied by the Bayesian
analysis and the proxy is given in (6). The weights are
therefore given by
w∗i =
fMVN
(Y,Xδ∗i ,Yvar)
fMVN
(
δ∗i , δ˜, s ˜δvar
) , (7)
where fMVN (·,μ,) is the probability density function of
the multivariate normal distribution with mean μ and
covariance matrix  and Yvar = τ 2∗β M1 + τ 2∗ω M2 +S. The
weights given in (7) are a direct extension of the impor-
tance sampling weights for conventional meta-analysis
given by Turner et al. [19]. Briefly, the constant of propor-
tionality in the Bayesian analysis and the constant due to
the uniform priors for the basic parameters are common
to all weights and so are ignored in (7); strictly speaking,
our formula for weights describes relative weights, but rel-
ative weighting is all that is required. The fact that the
constant of proportionality is common to all weights, and
so need not be evaluated, is the reason why importance
sampling is useful in Bayesian analysis. The lognormal
distributions are common to the numerator and denom-
inator of (7) and so cancel: they appear in the numerator
because the posterior distribution is proportional to the
prior, and they appear in the denominator because they
are used in the proxy distribution (6). Hence, after cancel-
lation, all that remains in the numerators of the weights is
the likelihood evaluated at the simulated values, which is
fMVN
(Y,Xδ∗i ,Yvar), and all that remains in the denomina-
tors is the density of the proxy distribution of δ∗ evaluated
at the simulated values, which is fMVN
(
δ∗i , δ˜, s ˜δvar
)
. In
principle, any heavy tailed proxy distribution could be
used instead of (6) but we see that the proxy distribution
is both intuitively appealing and results in a very sim-
ple formula for the weights. Since the weights depend on
the simulated values from the proxy distribution, they are
random and so we use an asterisk in their notation.
Weighted samples from the proxy distribution can then
be used to obtain any numerical summary of the posterior
distribution, including parameter estimates, moments,
and quantiles. For example, the posterior mean of the
between-study heterogeneity variance τ 2β may be esti-
mated from the simulated values of τ 2∗βi as
τ̂ 2β =
n∑
i=1
τ 2∗βi w∗i
n∑
i=1
w∗i
,
where n is the number of simulated values from the proxy
distribution. Monte Carlo errors of the estimated poste-
rior means, which we will present as estimates from the
Bayesian analyses, can be obtained in the way proposed
by Turner et al. [19] in their supplementary materials.
The full importance sampling code, and the data for both
examples, is also provided in the Additional file 4. We
also provide OpenBUGS code for both examples in the
Additional file 5, so that the results obtained using impor-
tance sampling and MCMC can be compared. This code
is taken from Jackson et al. [8] with trivial changes to
the prior specification. Since these methods implement
the same Bayesian analysis, they should be, to within
Monte Carlo error, in numerical agreement. This is the
case for both examples and together the two approaches
to Bayesian computation provide a convenient way to
confirm the accuracy of the numerical algorithms.
Likelihood-basedmethods
The Bayesian methods described above require the
specification of prior distributions for all parameters. In
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particular, they require priors for the unknown variance
components. A classical analysis makes fewer assump-
tions because it does not require the specification of prior
distributions. As explained above, the standard method
for making inferences about the average treatment effects
in the classical framework initially estimates the unknown
variance components and then treats them as known.
Analysis is then straightforward. However, the only classi-
cal method that has previously been proposed for estimat-
ing the unknown variance components in the model given
by (2) is based on the method of moments [7]. Although
this method is semi-parametric (in the sense of making no
distributional assumptions as part of the estimation pro-
cedure) and computationally undemanding, it is not based
on sufficient statistics and so is not fully efficient.
Likelihood-based methods are based on sufficient
statistics and are fully efficient in large samples. In the
Additional file 5, we provide R code for use with the
metafor package [23], that makes use of the rma.mv com-
mand to fit the model using likelihood-based methods.
Briefly, model (2) implies a (log) likelihood function that
depends on the parameters in δ and the two variance
components τ 2β and τ 2ω. However, for given values of the
variance components, the maximum likelihood estimate
(MLE) of δ is given by (3), and therefore model fitting
reduces to an optimization problem that involves max-
imizing the (log) likelihood over the two parameters τ 2β
and τ 2ω. This can be achieved using standard numerical
procedures, such as quasi-Newton or Nelder-Mead type
algorithms [24]. Once the MLEs of the variance compo-
nents are found (and hence the MLE of δ), the asymptotic
sampling variance of δˆ is given by (4) and inference about
δ can proceed as described earlier.
However, we follow the defaults of rma.mv and
use restricted maximum likelihood (REML) estimation
instead, although this can be changed by the analyst if
desired. In essence, REML uses a modification of the usual
likelihood in order to compensate for the fact that max-
imum likelihood estimates of variance components tend
to be biased downward [18]. Therefore, in the examples
below, we use the rma.mv command to obtain the REML
estimates of τ 2β and τ 2ω, which are then used as described
above to make inferences about the average treatment
effects. In the Additional file 5, we also show how the
rma.mv command can be used to fit a consistency model,
where we assume that τ 2ω = 0, and compare the models
with and without the consistency assumption, using the
likelihood ratio test.
There are further advantages to using a likelihood-
based approach for estimating the unknown variance
components. First, the asymptotic theory of maximum
likelihood provides a straightforward way to obtain
approximate confidence intervals and hypothesis tests
for all parameters, including the unknown variance
components. Below, we obtain confidence intervals for the
variance parameters using the profile likelihood method,
extending previous applications thereof in the context of
the standard random-effects model [25]. Obtaining these
types of inferences for the unknown variance components
when estimating them using the method of moments is
more difficult, and at present some form of bootstrapping
is most likely required for this purpose [7].
Second, by using likelihood-based methods, the esti-
mation procedure for alternative models (that could, for
example, involve more complicated assumptions for the
between-study variance or inconsistency variance com-
ponents) is immediate, although a challenge is still the
implementation and fine-tuning of the increasingly com-
plex numerical procedures required for obtaining the
ML/REML estimates. Conversely, when using the method
ofmoments, alternative estimation procedures are needed
for different types of model. Hence, the way to develop
estimation procedures that use the method of moments
for more complicated models involving additional vari-
ance components is not so obvious.
The likelihood-based results we obtain below for both
examples that follow are in good agreement with other
methods. The practical implementation of likelihood-
based estimation methods for models for network meta-
analysis, and the accompanying code for this purpose, is
one of the main contributions of this paper.
Other software
We implement our methods in R, and compare them to
results obtained using MCMC in BUGS software. How-
ever, our methods are not restricted to this software. In
principle, these methods could be implemented in SAS,
using PROC GLIMMIX, or in Stata. Existing Stata pack-
ages for undertaking network meta-analysis using existing
methods include network [26] and network graphs [27].
Further, MCMC methods may be undertaken in SAS
using PROCMCMC.
Results and discussion
In this section we apply our two new methods (Bayesian
estimation using importance sampling and informative
priors, and REML estimation) to two contrasting exam-
ples and discuss the results obtained. For the importance
samplingmethod, the analysis was undertaken using three
different prior distributions for inconsistency: using a
lognormal prior that is identical to the prior for the
between-study heterogeneity variance; using a lognormal
prior distribution with an expected value of half the prior
mean for heterogeneity, and using a lognormal prior with
an expected value of one tenth the prior mean for hetero-
geneity.We present the results for the second of these pos-
sibilities for the prior distribution of τ 2ω in the main paper,
while the results for the other prior distributions for τ 2ω
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can be found in the Additional file 5. When usingMCMC,
we used a single chain with a burn in of 100,000, and
1,000,000 iterations to make inferences. We appreciate
that multiple chains may be run as a check of convergence;
however, here, a comparison with the results obtained
using importance sampling provided satisfactory evidence
of convergence. When using importance sampling, no
burn in is required and we used 1,000,000 iterations to
make inferences. This number of iterations was chosen to
minimise MC error to compare the methods.
The Bayesian analyses using MCMC were implemented
in OpenBUGS, an open source version of WinBUGS [9].
All other computations were performed using R [28].
Bayesian analyses using importance sampling andMCMC
were implemented using the R and OpenBUGS code pro-
vided in the Additional file 3. All importance sampling
and MCMC inferential output for the examples are, to
within Monte Carlo error, in numerical agreement with
each other. Since both the MCMC and importance sam-
pling methods fit the same Bayesian model, checking this
agreement is in essence a check of the convergence of the
two methods. For all Bayesian analyses, we present poste-
rior means as estimates, but also include quantiles as the
posterior distribution of variance components is gener-
ally skew. The results for the likelihood-based estimation
method (REML) were obtained in R using the package
metafor [23], based on the code provided in the Additional
file 5.
Example one: prostate cancer
The first example dataset was collected and previously
analysed by Xiong et al. [29], who evaluate the compar-
ative efficacy and safety of a number of treatments for
prostate cancer. The dataset comprises seventeen two-
arm studies that compare eight categories of treatments:
A – Observational management (reference treatment);
B – prostatectomy; C – conventional radiotherapy (CR);
D – conventional radiotherapy hypofractionated (CR-
HF); E – 3D conformal low dose radiotherapy (CF-LD);
F – 3D conformal high dose radiotherapy (CF-HD);
G – 3D conformal low dose hypofractionated (CF-LD-
HF); and H – cryotherapy. The authors examined two
measures of efficacy, all-cause mortality and prostate
cancer-caused mortality; we have examined all-cause
mortality only, using the log odds ratio as the measure of
treatment effect. As all-cause mortality is an adverse out-
come and we use the log odds ratio, a negative treatment
effect indicates that the active treatment performs better
than the reference treatment.
The priors we used in the Bayesian analysis presented in
the main body of this paper are
τ 2β ∼ LN(−3.50, 1.262) and τ 2ω ∼ LN(−4.80, 1.682), so
that the lognormal prior distribution for the inconsis-
tency variance has an expected value of half of that of
the prior distribution for the between-study heterogeneity
variance. This represents the position that inconsistency is
to be anticipated in a network meta-analysis but it would
not usually be expected to be too severe. The estimates
obtained using a Bayesian analysis with these informative
prior distributions, implemented using both importance
sampling and OpenBUGS, are shown in Table 1, and
are in approximate agreement with those from Xiong
et al. [29] (see their Table 1, row 1), including the infer-
ences concerning the magnitude of the between-study
heterogeneity.
The estimates found using the likelihood-based method
are also shown in Table 1. The results are the same as those
from the consistency model (where τ 2ω = 0) as the incon-
sistency variance estimate is zero. Furthermore, the REML
results agree exactly with the results obtained using the
method of moments [7] because both the REML and the
moments-based estimates of both variance components
are zero. Hence for this example, the classical analyses col-
lapse to a common-effects analysis, where τˆ 2β = τˆ 2ω = 0. In
the Additional file 3, the likelihood ratio test shows no dif-
ference between the models because τˆ 2 = 0. The Bayesian
analysis also reflects the absence of between-study vari-
ation and inconsistency, because the Bayesian estimates
of these parameters are both close to zero. However, the
prior distributions for these parameters pull the posterior
means slightly away from zero.
Interestingly, the 95 % credibility interval for τ 2β based
on the Bayesian analyses (i.e., 0.00 to 0.08) is in close
agreement with the 95 % profile likelihood confidence
interval based on the likelihood-based analysis (i.e., 0.00
to 0.07). Since the latter does not incorporate any prior
information into the analysis, this suggests that inferences
about the amount of heterogeneity are mostly driven by
the information contained in the data at hand. On the
other hand, the credibility interval for τ 2ω (i.e., 0.00 to
0.11) is substantially narrower than the confidence inter-
val (i.e., 0.00 to 0.62). Therefore, relative to the amount
of information contained in the data about the degree of
inconsistency in the network, the prior for τ 2ω is exerting a
noticeable influence on the results of this analysis.
Also, while the Bayesian and classical inferences for the
basic parameters are in good agreement, the Bayesian
credible intervals are a little wider than the classical confi-
dence intervals. This is often the case in practice, because
the Bayesian analyses allow for the uncertainty in the
unknown variance components [7].
When the prior distribution for the inconsistency is
varied, the heterogeneity estimate remains similar (τˆ 2β =
0.02), while the inconsistency estimate decreases as the
expected mean of the prior is decreased (mean equal to
heterogeneity prior mean: τˆ 2ω = 0.04; one half: τˆ 2ω = 0.02;
one tenth: τˆ 2ω = 0.00, all in Additional files 1 and 4). The
choice of inconsistency prior is influential, which is to be
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Table 1 Results for the prostate cancer data using importance sampling, MCMC in OpenBUGS and REML estimation. Estimates are log
odds ratios
Parameter Estimate SD MCSE 2.5 % 50 % 97.5 %
Importance sampling B: Prostatectomy δAB -0.25 0.19 0.0015 -0.63 -0.25 0.11
C: CR δAC -0.16 0.34 0.0033 -0.82 -0.15 0.50
D: CR-HF δAD -0.32 0.41 0.0038 -1.13 -0.32 0.49
E: CF-LD δAE -0.31 0.30 0.0030 -0.90 -0.31 0.27
F: CF-HD δAF -0.35 0.35 0.0033 -1.02 -0.35 0.33
G: CF-HF-LD δAG -0.66 0.87 0.0085 -2.34 -0.67 1.07
H: Cryotherapy δAH -0.27 0.53 0.0051 -1.32 -0.29 0.80
Heterogeneity τ 2β 0.02 0.02 0.0002 0.00 0.01 0.08
Inconsistency τ 2ω 0.02 0.04 0.0002 0.00 0.01 0.11
MCMC B: Prostatectomy δAB -0.25 0.19 0.0011 -0.63 -0.24 0.12
C: CR δAC -0.16 0.34 0.0036 -0.83 -0.16 0.51
D: CR-HF δAD -0.32 0.42 0.0039 -1.14 -0.32 0.50
E: CF-LD δAE -0.31 0.30 0.0030 -0.90 -0.31 0.28
F: CF-HD δAF -0.35 0.35 0.0036 -1.03 -0.35 0.34
G: CF-HF-LD δAG -0.63 0.86 0.0100 -2.33 -0.64 1.06
H: Cryotherapy δAH -0.27 0.54 0.0048 -1.32 -0.27 0.78
Heterogeneity τ 2β 0.02 0.02 0.0001 0.00 0.01 0.08
Inconsistency τ 2ω 0.02 0.04 0.0003 0.00 0.01 0.11
Parameter Estimate SE CI lower CI upper p-value
REML estimation B: Prostatectomy δAB -0.22 0.11 -0.43 -0.01 0.04
C: CR-CF δAC -0.17 0.28 -0.72 0.39 0.56
D: CR-HF δAD -0.33 0.32 -0.96 0.31 0.31
E: CF-LD δAE -0.32 0.25 -0.80 0.17 0.21
F: CF-HD δAF -0.35 0.28 -0.90 0.19 0.20
G: CF-HF-LD δAG -0.65 0.83 -2.27 0.97 0.43
H: Cryotherapy δAH -0.28 0.47 -1.20 0.65 0.56
Heterogeneity τ 2β 0.00 – 0.00 0.07 –
Inconsistency τ 2ω 0.00 – 0.00 0.62 –
CR=conventional radiotherapy; HF=hypofractionated; CF=3D conformal; LD=low dose; HD=high dose
expected as we are estimating nine parameters (the seven
basic parameters and two variance components) using
seventeen comparisons.
To summarise, our analyses are in reasonable agreement
and suggest that there is little between-study heterogene-
ity or inconsistency in the study results. This in turn
suggests that the true underlying treatment effects are
very similar in all studies in the population. The analyses
also suggest that all eight treatments have a similar average
effect. Hence the overall picture from our analysis is that,
in terms of treatment efficacy for the outcome of all-cause
mortality, there is little to choose between the treatments
in any study.
Example two: topical antibiotics
The second set of example data is from a Cochrane
Systematic Review entitled “Topical antibiotics without
steroids for chronically discharging ears with underly-
ing eardrum perforations” [30]. The dataset comprises
thirteen studies (three three-arm studies, ten two-arm
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studies) and compares three pharmacological treatments
(B – topical quinolone antibiotic; C – topical non-
quinolone antibiotic; and D – topical antiseptic) to no
treatment (A). This dataset was analysed by Jackson et
al. [7] using the same model as used in this paper, but
using the method of moments. As the treatment effects
are log odds ratios comparing the other treatments to
treatment A, and the outcome is harmful (treatment fail-
ure due to persistent discharge), negative basic parameters
indicate that treatments B, C and D are more beneficial
than treatment A (no treatment).
The priors we used in the Bayesian analysis presented
in the main paper are τ 2β ∼ LN(−2.29, 1.582) and τ 2ω ∼
LN(−3.64, 1.952). Although one of the treatments, treat-
ment A (“no treatment") is not pharmacological, we make
the pragmatic decision to use a prior distribution for
heterogeneity for pharmacological vs. pharmacological
intervention comparisons. The Bayesian results are shown
in Table 2 and and are set out in a similar way as the
table for the first example. The estimates of the treatment
effects are similar to those shown in Jackson et al. [7]
(see their Table 4). The estimates of the between-study
and inconsistency variances in Table 2 are smaller than
the corresponding Bayesian estimates in Jackson et al.
(τˆ 2β = 0.56, τˆ 2ω = 0.96), where vague uniform priors from
0 to 5 were placed on τβ and τω, but are still large enough
to be described as high. This suggests that there is con-
siderable between-study variation and also inconsistency
in treatment effect estimates across designs. Furthermore,
the posterior standard deviations of the basic parame-
ters in Table 2 are also smaller than those of the previous
Bayesian analyses [7]. Bayesian credible intervals are often
wider than the corresponding classical confidence inter-
vals, and the smaller posterior standard deviations (and
resulting narrower credible intervals) in comparison to
the classical results in this example can be explained by the
use of informative priors. The informative priors therefore
have considerable impact in this example. Full results from
the analysis using uniform priors are available in Jackson
et al., [7] (their Table 4).
The estimates found using the likelihood-based method
are also shown in Table 2. Again we infer that consider-
able inconsistency is present (τˆ 2ω = 0.54), so this time the
results differ from those that are obtained using the cor-
responding consistency model. Comparing the model fits
using the likelihood ratio test shows no statistically sig-
nificant evidence of an improvement in model fit. The
estimated between-study heterogeneity variance is also
Table 2 Results for the topical antibiotics data using importance sampling, MCMC in OpenBUGS and REML estimation. Estimates are
log odds ratios
Parameter Estimate SD MCSE 2.5 % 50 % 97.5 %
Importance B: Quinolone δAB -1.85 0.62 0.0012 -3.18 -1.82 -0.69
sampling C: Non-quinolone δAC -1.31 0.71 0.0014 -2.78 -1.29 0.03
D: Antiseptic δAD -0.64 0.65 0.0013 -2.01 -0.62 0.60
Heterogeneity τ 2β 0.28 0.31 0.0006 0.01 0.18 1.09
Inconsistency τ 2ω 0.22 0.38 0.0007 0.00 0.08 1.20
MCMC B: Quinolone δAB -1.85 0.62 0.0052 -3.15 -1.82 -0.68
C: Non-quinolone δAC -1.30 0.71 0.0061 -2.77 -1.28 0.04
D: Antiseptic δAD -0.64 0.65 0.0053 -1.99 -0.62 0.61
Heterogeneity τ 2β 0.28 0.31 0.0017 0.01 0.18 1.09
Inconsistency τ 2ω 0.22 0.38 0.0030 0.00 0.08 1.19
Parameter Estimate SE CI lower CI upper p-value
REML B: Quinolone δAB -1.97 0.68 -3.30 -0.65 <0.01
estimation C: Non-quinolone δAC -1.40 0.81 -2.98 0.18 0.08
D: Antiseptic δAD -0.66 0.72 -2.07 0.75 0.36
Heterogeneity τ 2β 0.10 – 0.00 1.67 –
Inconsistency τ 2ω 0.54 – 0.00 3.96 –
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larger than zero (τˆ 2β = 0.10), but not as large as the
corresponding estimate using the method of moments
[7]. However, the sums of the REML- and moment-based
point estimates of the variance components (i.e., τˆ 2β + τˆ 2ω)
are in better agreement. Since the marginal variance of
any entry of Y is equal to τ 2β + τ 2ω plus the correspond-
ing within-study variance, we would anticipate this type of
agreement. However, the REML analysis attributes more
of the total variation in the data to inconsistency than
the previous moment-based analysis. The new results
obtained here, when compared to those reported pre-
viously, nicely illustrate the difficulty in separating the
two unknown variance components in small samples. If
desired, a user could additionally perform interval esti-
mation for the sum of the variance components, with the
intuition that this sum will be better identified than the
individual variance components.
The relevance of the informative priors for τ 2β and τ 2ω
also becomes quite apparent when we compare again the
95 % credibility and confidence intervals for these parame-
ters. Specifically, the profile likelihood confidence interval
for τ 2ω is very wide (i.e., 0.00 to 3.96), while the credibil-
ity interval is much narrower (0.00 to 1.20 or 1.19, for the
importance sampling and MCMC, respectively). The lat-
ter is based not only on the information contained in the
data about the degree of inconsistency in the network, but
also the information contained in the prior distribution.
In fact, the 2.5th and 97.5th percentiles of the lognormal
prior distribution for τ 2ω are 0.03 and 1.20, respectively,
so the inferences about this parameter in the Bayesian
analyses appear to be driven to a large extent by what
was specified via the prior. This is further shown by not-
ing the estimates of the variance components when using
different informative priors: When the expected mean of
the inconsistency prior is equal to that of the hetero-
geneity prior, the estimates obtained using importance
sampling (and MCMC) are τˆ 2β = 0.22, τˆ 2ω = 0.35. When
the expected mean is one tenth, the estimates are τˆ 2β =
0.37, τˆ 2ω = 0.06 (see Additional files 1 and 4). As with the
first example, the choice of inconsistency prior is influ-
ential; in this instance, we are estimating six parameters
using sixteen comparisons.
With respect to the basic parameters, inferences based
on the Bayesian analyses, the likelihood-based analysis,
and the method of moments are all in relatively good
agreement, with quinolone yielding the largest point esti-
mate of treatment effect, which we also infer to be more
effective than no treatment.
Conclusions
We have presented two new methods for fitting models
for network meta-analyses that include random inconsis-
tency effects. Bothmethods are described in order to fit an
existing model for network meta-analysis. The first new
method implements a Bayesian analysis using importance
sampling and informative lognormal prior distributions
for the unknown variance components. The second new
method uses likelihood-based methods, and in particular
REML estimation, to fit the model. Although importance
sampling and REML estimation are not methodologically
new, to our knowledge this is the first time these methods
have been applied in this particular setting.
Although we present our methods in terms of the model
proposed by Jackson and colleagues, we can modify the
model to allow different forms of inconsistency variance
components by using a different matrixM2. For example,
by modifying this matrix we can describe loop incon-
sistency models [7] and also other types of models that
use random-inconsistency effects. Hence our methods are
very easily modified to fit alternative models: one sim-
ply replaces M2 with a different matrix and proceeds
as described above. We assume random inconsistency
effects so that the basic parameters can be interpreted as
average treatment effects across the network, so that ‘the
end justifies the means’. However, the case for using fixed
inconsistency effects instead can also be made, mainly
on the grounds that the distributional assumptions made
when using random inconsistency effects are strong and
may be unrealistic [12].
The model could also be extended with further vari-
ance parameters, by introducing more products of M
matrices with corresponding variance components. For
example, Gumedze and Jackson [31] describe a random
effects variance shift model for detecting and accommo-
dating outliers in conventional univariate meta-analyses.
The same idea could be applied in the present context,
by adding random shift effects for particular contrasts,
studies, and/or designs.
We have focused on estimation in this paper. However,
alternative forms of inference, such as treatment ranking,
I2 statistics, prediction intervals, model diagnostics, and
so on are also very important and are likely to form the
subject of future work. The focus of our attention on the
two new estimation methods developed here should not
be taken to mean that other inferential aspects should
be ignored. Rather we emphasise estimation in this paper
because this is the aspect of the methodology for network
meta-analysis that this work is intended to extend.
The model provides a way of estimating inconsistency
in a network meta-analysis. When it is clear that inconsis-
tency is considerable, we would strongly discourage pro-
ceeding with a network meta-analysis. One might choose
instead to re-evaluate the criteria for study inclusion, or
examine where the inconsistency occurs [10]. When there
is strong evidence that inconsistency is low, one might
consider making the consistency assumption. However,
we would still recommend using a random-effects model.
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When information regarding inconsistency is low and its
estimate may be dominated by its prior, a sensitivity anal-
ysis may be undertaken: a range of priors may be used,
or the results may be compared to a variety of frequentist
analyses.
This work extends the methodology of using informa-
tive priors for the between-study heterogeneity variance
to also using informative priors for the inconsistency
variance. To our knowledge, informative priors have not
previously been used to inform the estimation of incon-
sistency parameters in network meta-analysis. As possible
future work, data-based predictive distributions for the
inconsistency variance in network meta-analysis in vari-
ous settings could be produced in an analogous manner
as that undertaken by Turner et al. [19] for the between-
study heterogeneity. We have chosen informative priors
for inconsistency that have an expected mean of one half
that of the between-study heterogeneity, and used other
ratios as a form of sensitivity analysis. However, other
approaches could be considered. For example, further
empirical work could investigate the relationship between
between-study heterogeneity and inconsistency, possibly
by placing vague priors on both and examining the ratio
of estimates in various settings.
The use of Bayesian methods facilitates making state-
ments about the uncertainty in the estimated between-
study heterogeneity variance and the inconsistency
variance, which is preferable to reporting point esti-
mates only [32]. Likelihood-based methods can also be
used to obtain corresponding confidence intervals, but
Bayesian methods also automatically take the uncertainty
in these variance components into account when mak-
ing inferences about the average treatment effects. How-
ever, this benefit of the Bayesian approach comes at the
cost of making more assumptions via the prior distribu-
tions. For example, we make repeated use of the prior
knowledge afforded by Turner et al. [19] (because we
use it to form two prior distributions) without recognis-
ing that fact in the analysis. Another criticism is that,
since inconsistency in network meta-analysis is less well
understood than between-study variation, it is quite rea-
sonable to assert that we have less prior knowledge about
τ 2ω than τ 2β , so that the prior distribution of the for-
mer unknown variance should be more diffuse than the
prior distribution of the latter one. This could be taken
into account by scaling V by a factor of greater than
one before using (5) to derive the prior for τ 2ω. For now,
we are content to use our suggested procedure as a
pragmatic way to derive informative prior distributions
for the inconsistency variance. We would be pleased to
replace this procedure for obtaining informative priors
for τ 2ω with priors derived using a modelling approach
like that of Turner et al. [19], if and when they become
available.
An advantage of a Bayesian approach is flexibility: For
example, they allow us to take exact likelihood approaches
and specify non-normal random-effects distributions if
desired. Further, future work could extend the presented
methods to allow the specification of the binomial within-
study likelihood, which is preferable for binary data. Both
Bayesian and classical methods have their advantages and
disadvantages, and so we present estimation methods in
both of these conceptual frameworks.
The full computing code for both new methods is
included in the Additional file 2, accompanied by the
two working examples described above. In the case that
a likelihood-based approach is preferred, models can be
fit within an existing package. This feature of the metafor
package has never been presented before. Both new esti-
mation methods have been found to give results compa-
rable to those obtained using existing methods in our two
contrasting examples.
Implementing Bayesian analyses using bothMCMC and
importance sampling, as we have done, is a practical way
to verify Bayesian analyses that use MCMC methods. We
recommend that authors consider this in application.
In summary, we have developed two new estimation
methods for models for network meta-analysis with ran-
dom inconsistency effects. Our new Bayesian method-
ology can be undertaken without recourse to MCMC
or the Win/OpenBUGS software and our new classical
methodology means that the metafor package can now
be used to fit models of this type. We hope that this
paper and the accompanying computing code will help to
make network meta-analysis more accessible to applied
researchers.
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